# Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

> **NCT02052648** · PHASE1,PHASE2 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 160 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioma
- Gliosarcoma
- Malignant Brain Tumor

## Interventions

- **DRUG:** Indoximod
- **DRUG:** Temozolomide
- **DRUG:** Bevacizumab
- **RADIATION:** Stereotactic Radiation

## Key facts

- **NCT ID:** NCT02052648
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-04-18
- **Final completion:** 2019-06-20
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052648, "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02052648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*